1. Home
  2. MGNX vs CURV Comparison

MGNX vs CURV Comparison

Compare MGNX & CURV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$1.72

Market Cap

115.8M

Sector

Health Care

ML Signal

HOLD

Logo Torrid Holdings Inc.

CURV

Torrid Holdings Inc.

HOLD

Current Price

$1.11

Market Cap

122.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGNX
CURV
Founded
2000
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Clothing/Shoe/Accessory Stores
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
115.8M
122.0M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
MGNX
CURV
Price
$1.72
$1.11
Analyst Decision
Hold
Hold
Analyst Count
5
6
Target Price
$3.20
$1.59
AVG Volume (30 Days)
921.0K
443.9K
Earning Date
03-19-2026
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$127,626,000.00
$1,039,486,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$0.94
52 Week High
$2.95
$6.95

Technical Indicators

Market Signals
Indicator
MGNX
CURV
Relative Strength Index (RSI) 48.42 43.69
Support Level $1.66 $1.06
Resistance Level $1.83 $1.18
Average True Range (ATR) 0.13 0.09
MACD -0.02 -0.01
Stochastic Oscillator 29.58 22.45

Price Performance

Historical Comparison
MGNX
CURV

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

About CURV Torrid Holdings Inc.

Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.

Share on Social Networks: